Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:2799-2800
doi: 10.1161/CIRCULATIONAHA.107.705848
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carabello, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carabello, B. A.
Related Collections
Right arrow Other Treatment
Right arrowRelated Article

(Circulation. 2007;115:2799-2800.)
© 2007 American Heart Association, Inc.


Editorial

Aortic Stenosis

Two Steps Forward, One Step Back

Blase A. Carabello, MD

From the Department of Medicine, The W.A. "Tex" and Deborah Moncrief, Jr Chair, Baylor College of Medicine, Medical Care Line Executive, and Veterans Affairs Medical Center, Houston, Tex.

Correspondence to Blase A. Carabello, MD, Michael E. DeBakey VAMC, 2002 Holcombe Blvd, Houston, TX 77030.


Key Words: Editorials • aorta • stenosis • valves • ventricular ejection fraction


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 

Severe symptomatic aortic stenosis (AS) is a lethal disease, the only effective therapy for which is mechanical relief of the obstruction to outflow, ie, aortic valve replacement (AVR). Generally held tenets about AS include the following. (1) Patients with preserved systolic function have an excellent outcome after AVR.1 (2) Patients with reduced ejection fraction (EF) and high afterload also have an excellent response to AVR because AVR reduces afterload and allows ejection performance to return toward normal.2,3 (3) Patients with low flow, reduced EF, and pseudo-AS would not benefit from AVR. Pseudo-AS has been defined as a condition in which calculated aortic valve area falsely overestimates the severity of AS when aortic valve area is calculated at low flow.4,5 Because in such cases the AS is in fact not severe, it has been reasoned that AVR would not be of benefit. (4) Patients with truly severe AS, low EF, and low gradient benefit from AVR when such patients demonstrate inotropic reserve.6 (5) Even some low-EF, low-gradient patients without inotropic reserve benefit from AVR.7 However, 2 studies of AS published in this issue of Circulation raise many interesting questions about our management of patients with AS.8,9 These studies help to confirm some of our concepts of managing this disease while raising questions about others.

Articles pp 2848 and 2856

The study by Hachicha et al8 seems to confirm at least 1 of the aforementioned concepts: that AS patients with only mild left ventricular (LV) systolic dysfunction have an excellent outcome after . . . [Full Text of this Article]


Related Article:

Issue Highlights
Circulation 2007 115: 2789. [Extract] [Full Text]



This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
J. P. Dal-Bianco, B. K. Khandheria, F. Mookadam, F. Gentile, and P. P. Sengupta
Management of Asymptomatic Severe Aortic Stenosis
J. Am. Coll. Cardiol., October 14, 2008; 52(16): 1279 - 1292.
[Abstract] [Full Text] [PDF]